HOME >> BIOLOGY >> NEWS
Cancer pain control possible with gene therapy

PITTSBURGH, Oct. 15 By "programming" a herpes simplex virus to deliver a gene-mediated pain-blocking protein at the cellular level, University of Pittsburgh researchers have been able to significantly reduce cancer-related pain in mice with tumors, the researchers report in the November issue of the journal Annals of Neurology. The paper, "Herpes vector-mediated expression of proenkephalin reduces bone cancer pain," is now available online at the journal's Web site, http://www.interscience.wiley.com/jpages/0364-5134/.

"Chronic pain is notoriously difficult to treat effectively," said co-author Joseph Glorioso, Ph.D., chairman of the department of molecular genetics and biochemistry and director of the Molecular Medicine Institute at the University of Pittsburgh School of Medicine, and president of the American Society of Gene Therapy. "We've been able to show that using this virus can significantly reduce bone cancer pain at least in mice."

The investigators are pursuing necessary approvals to begin a clinical trial in patients with severe pain resulting from metastatic cancer, and hope to start enrolling patients sometime next year.

"We are excited about the possibility that this approach may help to control pain in patients who can't get complete relief from the maximum current treatment," said senior author David Fink, M.D., professor of neurology and molecular genetics and biochemistry at the University of Pittsburgh School of Medicine and chief of neurology and director of the Geriatric Research Education and Clinical Center at the Veterans Administration Pittsburgh Healthcare System.

Drs. Fink, Glorioso and their colleagues created an inactivated herpes simplex virus that carries the human gene for proenkaphalin, a naturally occurring painkilling peptide, a combination of amino acids.

Mice with tumors in a leg bone that received injections with the alte
'"/>

Contact: Michele Baum
412-647-3555
University of Pittsburgh Medical Center
15-Oct-2002


Page: 1 2

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Cancer gene MYC emerging as key research target
5. Cancer patient, heal thyself
6. USC researcher named General Motors Cancer Research Scholar
7. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
8. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
11. National Cancer Gene Therapy Foundation gives $4.0 million in research grants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/18/2018)... ... October 18, 2018 , ... ... industry, announces the grand opening of its new West Cambridge flagship facility scheduled ... rental suites, a wet lab, tissue culture, necropsy and surgery rooms will give ...
(Date:10/17/2018)... ... October 17, 2018 , ... Maintenance of Certification (MOC) adds ... percent of physicians surveyed by MDLinx, a medical news, information, and education website. ... revealed that many physicians are frustrated with the mandated MOC requirements that the ...
(Date:10/16/2018)... ... ... Our own cells may be the answer to eliminating chronic neck or ... and pain management specialist Jason Arora, DO, who says using a patient’s blood plasma, ... patient’s bone marrow are proving effective therapies for eliminating discogenic pain, namely pain caused ...
Breaking Biology News(10 mins):
(Date:10/17/2018)... (PRWEB) , ... October 17, 2018 , ... ... spp. and Phytophthora spp. have been validated by USDA’s Animal and Plant Health ... users can use the assays with confidence and trust, knowing they will be ...
(Date:10/16/2018)... ... October 15, 2018 , ... Since the inception ... histopathology slides by eye wherein key features are used for classification. While this ... it is highly limited in that it is a qualitative and low-throughput approach ...
(Date:10/11/2018)... ... 10, 2018 , ... Boston Biotech Conferences, creator of exclusive ... PhD, as its new CEO. , Dr. Nelson has over 20 years of ... Most recently, Dr. Nelson was VP of Business Development, Marketing and Strategic Alliances ...
(Date:10/5/2018)... ... October 04, 2018 , ... ... has received a Spine Technology Award from Orthopedics This Week during the 2018 ... The Power T Handle is a surgical instrument that delivers operating room efficiencies ...
Breaking Biology Technology:
Cached News: